Evidence for the Existence of a Multidrug Efflux Transporter Distinct from NorA in Staphylococcus aureus
AUTOR(ES)
Kaatz, Glenn W.
FONTE
American Society for Microbiology
RESUMO
A Staphylococcus aureus norA disruption mutant was created by allelic replacement. Exposure of this mutant to norfloxacin produced SA K1748, a derivative with raised fluoroquinolone MICs, found to be the result of a grlA mutation, and raised organic cation MICs. Ethidium and enoxacin uptake was identical in SA K1748 and its parent, but pre-exposure of SA K1748 to organic cations caused a reduction in ethidium uptake as a result of increased efflux. Altered ethidium uptake and efflux, as well as increased MICs of other organic cations, suggest that SA K1748 possesses a non-NorA multidrug efflux transporter that is inducible by its substrates.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=89884Documentos Relacionados
- Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter.
- Multiple Novel Inhibitors of the NorA Multidrug Transporter of Staphylococcus aureus
- Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus.
- Expression of the Multidrug Resistance Transporter NorA from Staphylococcus aureus Is Modified by a Two-Component Regulatory System
- The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein.
